Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Indapta, Lonza Form Immuno-oncology Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Indapta, Lonza Form Immuno-oncology Partnership

Lonza to provide process development, clinical manufacturing and regulatory support for IND filing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Indapta Therapeutics, a biotechnology company focused on developing and commercializing a first-in-class, off-the-shelf, non-engineered, allogeneic G-NK (FcRγ-deficient Natural Killer) cell therapy to treat multiple cancers, and Lonza have entered a strategic partnership.
 
Under the terms of the agreement, Lonza will manufacture Indapta’s allogeneic G-NK cell therapy under current good manufacturing practices (cGMP) for use in clinical studies. Indapta will leverage Lonza’s process development capabilities and expertise to ensure a robust, reproducible and scalable cGMP process. Process development and manufacturing will take place in Lonza’s state-of-the-art cell and gene therapy manufacturing facility in Houston, TX.
 
“We believe our first-in-class, off-the-shelf, allogeneic G-NK cell therapy will drive the next critical phase in the evolution of cancer therapies following CAR T-cell therapies,” said Guy DiPierro, founder and chief executive officer, Indapta Therapeutics. “Current autologous CAR T-cell therapies have proven efficacy in various hematologic cancers but have been beset with serious clinical and manufacturing challenges. By providing an off-the-shelf solution with our G-NK cell therapy, we can eliminate the need for a patient-specific therapy. Additionally, because our investigational cell therapies are not engineered, they are likely to be more effective, less costly and have a simpler regulatory pathway.”
 
Scott Waldman, chief strategy officer, Lonza, said, “Indapta’s world-class team of NK cell scientists and clinicians and cell therapy experts has created an innovative off-the-shelf immuno-oncology therapy based on a subset of cancer-killing NK cells that could make a truly meaningful impact in the treatment of hematologic malignancies and solid tumors.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics